LifeSci Capital Reaffirms Buy Rating on Centessa Pharmaceuticals (CNTA) with a $39 PT, Anticipates Key Orexin Pipeline Data
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best up and coming stocks with huge upside potential.
Centessa Pharmaceuticals Plc (CNTA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 8,403,000 | $110,415,420 | +21% | 0.19% |
| 2. | VenBio Select Advisor Kurt Von Emster | 5,000,000 | $65,700,000 | +24% | 1.15% |
| 3. | Farallon Capital Thomas Steyer | 4,529,318 | $59,515,239 | +5% | 0.26% |
| 4. | Siren L.L.C. Raymond Debbane | 3,460,029 | $45,464,781 | +17% | 2.35% |
| 5. | Commodore Capital Egen Atkinson And Michael Kramarz | 3,298,289 | $43,339,517 | +40% | 3.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $12.73 | 417,646 | $5,315,004.76 | 462,585 | 2025-05-16 | Filing | |
| $12.24 | 44,939 | $550,237.61 | 44,939 | 2025-05-15 | Filing | |
| $4.63 | 10,000 | $46,284.00 | 38,000 | 2022-06-24 | Filing | |
| $9.74 | 5,000 | $48,700.00 | 28,000 | 2022-02-02 | Filing | |
| $9.05 | 27,500 | $248,754.00 | 27,500 | 2022-01-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.00 | 35,000 | $840,000.00 | 121,503 | 2025-09-24 | Filing | |
| $22.02 | 742 | $16,339.80 | 197,394 | 2025-09-16 | Filing | |
| $21.33 | 7,430 | $158,506.42 | 198,136 | 2025-09-16 | Filing | |
| $21.85 | 6,000 | $131,100.60 | 105,386 | 2025-09-15 | Filing | |
| $22.00 | 25,000 | $550,000.00 | 121,503 | 2025-09-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,963,157 | $262,315,883 | 61.4% | |
| 2. | 9,961,789 | $130,897,907 | 100% | |
| 3. | 9,681,818 | $127,219,089 | 3.51% | |
| 4. | 6,532,768 | $85,816,688 | 0.04% | |
| 5. | 4,293,411 | $56,415,421 | 7.31% |
News See All
10 Best Up and Coming Stocks with Huge Upside Potential
On August 20, Andres Garcia-Amaya, Zoe Financial CEO, joined 'The Exchange' on CNBC to discuss how IPO pops will draw in private companies to become public.
Truist Initiates Buy on Centessa Pharmaceuticals (CNTA) with $30 PT, Cites Orexin Drug Potential
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the biotech stocks to buy according to Wall Street analysts.
Centessa Pharmaceuticals Advances Neurological Drug ORX142 to Clinical Trials
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best low priced pharma stocks to buy now. On July 4, Nxera Pharma Co.
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
Centessa Pharmaceuticals Receives FDA Clearance for New Drug ORX142, Initiates Phase 1 Study
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the best biotech stocks to invest in now.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential
On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on 'Closing Bell' to talk about the impact of tariffs on small caps.
12 Best Medical Stocks To Buy Under $20
The medical industry plays a crucial role in ensuring the health and safety of populations.
12 Best Growth Stocks Under $25 to Buy Now
Most experts agree that the AI wave is not over yet.